Icotinib vs Osimertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Icotinib

Marketed by Betta Pharmaceuticals Co.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT01040780 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial with 200 participants assigned to icotinib and 199 to gefitinib, and its primary endpoint was the clinical measure of progression-free survival. Although the reported median favored icotinib, the statistical significance of the primary comparison is not stated, so the result is unclear rather than definitively positive.

Next expected readout: October 2030 · NCT07458919 (registry estimate)

Reported efficacy

Progression Free Survival (12 months): Primary endpoint, PFS (CONVINCE trial): icotinib 11.2 months vs cisplatin/pemetrexed+pemetrexed maintenance 7.9 months; HR 0.61 (95% CI 0.43-0.87), p=0.006 (met)

Result source: NCT01719536

Osimertinib · Tagrisso

Marketed by AstraZeneca

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02151981 · Phase 3 · completed

The trial was randomized and actively controlled, with 279 patients receiving osimertinib and 140 receiving platinum-based chemotherapy, but treatment assignment was not blinded. Its primary clinical endpoint, investigator-assessed progression-free survival, favored osimertinib significantly (hazard ratio 0.30; p<0.001), supporting moderate-strength evidence rather than the strongest level because the study was open-label.

Next expected readout: November 2026 · NCT05998993 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6) (met)

Result source: NCT02151981

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIcotinibOsimertinib
PFS, median4.6 vs 3.4vs Gefitinibn 199NCT01040780
1 other result
19.5 vs 22.0vs Gefitinibn 45NCT02856893
1 other result
OS, median13.3 vs 13.9vs Gefitinibn 199NCT01040780—Not posted · NCT05015608
ORR—Not posted · NCT0420607276%bn 25NCT02789345
Duration of response, median—Not posted · NCT0420607213.4bn 19NCT02789345

PFS, median

Icotinib
4.6 vs 3.4vs Gefitinibn 199NCT01040780
1 other result
Osimertinib
19.5 vs 22.0vs Gefitinibn 45NCT02856893
1 other result

OS, median

Icotinib
13.3 vs 13.9vs Gefitinibn 199NCT01040780
Osimertinib
—Not posted · NCT05015608

ORR

Icotinib
—Not posted · NCT04206072
Osimertinib
76%bn 25NCT02789345

Duration of response, median

Icotinib
—Not posted · NCT04206072
Osimertinib
13.4bn 19NCT02789345
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Icotinib: 3 of 4 rows · Osimertinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIcotinibOsimertinib
Dropout rate
0.5%a
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
0%
NCT02264210 · Phase 2 · registry result, not featured evidence
62.3%b
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
100%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
77.3%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
—
NCT02264210 · Phase 2 · registry result, not featured evidence
3.8%b
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
0%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
4.5%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
6.5%a
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
6.3%
NCT02264210 · Phase 2 · registry result, not featured evidence
17%b
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
33.3%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
36.4%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
rash 40.5%
diarrhea 21.5%
pain 18%
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
rash 39.7% (placebo 0%)
diarrhoea 20.6% (placebo 0%)
pain 11.1% (placebo 0%)
NCT02264210 · Phase 2 · registry result, not featured evidence
b
diarrhea 50.9%
dry skin 41.5%
weight loss 35.8%
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
cough 100%
diarrhoea 100%
arthralgia 66.7%
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 63.6%
hypertension 63.6%
decreased appetite 40.9%
NCT02789345 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Icotinib

Stable Disease 47.7% (n=199) vs 47.7% (n=196) Gefitinib
absolute value · percentage points
Stable Disease (SD)
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Progressive Disease 21.1% (n=199) vs 20.5% (n=196) Gefitinib
absolute value · percentage points
Progressive Disease (PD)
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Disease Control 75.4% (n=199) vs 74.9% (n=196) Gefitinib
absolute value · percentage points
Disease Control (CR+PR+SD)
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Disease-Free Survival 96.1 vs 84 placebo % of time @ 156wk
absolute value · % of time
NCT02264210 · Phase 2 · registry result, not featured evidence

Osimertinib

PFS18 51.1% (n=45) vs 67.2% (n=47) Gefitinib @ 78wk
responder rate · % of participants
NCT02856893 · Phase 2 · registry result, not featured evidence
Time to Progression 19.48 vs 10.81 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
ORR 0.889 vs 0.656 Gefitinib count
event count · count
NCT02856893 · Phase 2 · registry result, not featured evidence
Intracranial PFS 34.3 vs 24.44 Gefitinib months
absolute value · months
NCT02856893 · Phase 2 · registry result, not featured evidence
PFS2 25.76 vs 21.98 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
ORR 76% (n=25)
responder rate · % of participants
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Disease Control 92% (n=25)
responder rate · % of participants
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Duration of Response 13.37 months
time to event · months
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
PFS 11.04 months
time to event · months
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Overall Survival NA months
time to event · months
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Icotinib's landscape · Osimertinib's landscape